Study Reinforces BRAF-MEK Inhibition Over Anti-BRAF Only in Advanced Melanoma
Combined BRAF-MEK inhibition for advanced BRAF-mutant melanoma led to significantly better progression-free survival (PFS) as compared with single-agent BRAF inhibition, according to a randomized trial. Patients who received encorafenib (Braftovi) plus binimetinib (Mektovi) had a median PFS of 12.9 months as compared with 9.2 and 7.4 months for two cohorts treated with encorafenib alone. The […]
BRAF-MEK Inhibition Achieves ‘Near Universal’ Response in Rare Brain Tumor
Targeted BRAF-MEK inhibition resulted in a response in nearly all patients with untreated BRAF V600E–mutated papillary craniopharyngioma, according to results from a small phase II study. Of 16 evaluable patients treated with the BRAF inhibitor vemurafenib (Zelboraf) and the MEK inhibitor cobimetinib (Cotellic) over several monthly cycles, 15 had a durable, objective partial response or […]
Studies Question Role of CDK4/6 Inhibitors in First-Line Advanced Breast Cancer
CHICAGO — Upfront CDK4/6 inhibition or second-line use in advanced hormone receptor (HR)-positive/HER2-negative breast cancer led to similar cumulative progression-free survival (PFS) in a large randomized trial. Patients who received a CDK4/6 inhibitor plus an aromatase inhibitor (AI) as initial therapy and fulvestrant in the second line had a median PFS of 31.0 months at […]
Two PARP Inhibitors Impress as First-Line Add-Ons in mCRPC
Adding PARP inhibition to first-line abiraterone (Zytiga) reduced the risk of radiographic progression or death in metastatic castration-resistant prostate cancer (mCRPC), a pair of phase III studies showed. In PROpel, patients who received olaparib (Lynparza) along with abiraterone plus prednisone had a roughly 8-month improvement in median radiographic progression-free survival (rPFS) versus those assigned placebo […]
New path to treat advanced triple-negative breast cancer
A new study by researchers at Yale Cancer Center shows inhibition of the CECR2 gene prevents triple-negative breast cancer from advancing or metastasizing. The discovery is an early step in finding new therapeutics for triple-negative breast cancer (TNBC), one of the most difficult disease sub-types to treat. The findings are published online today in the […]